在三阴性乳腺癌模型中,MCAK 抑制剂诱导积体
bioRxiv : the preprint server for biology
|July 3, 2023
概括
针对MCAK,一种在三阴性乳腺癌 (TNBC) 中过度表达的蛋白质,提供了一种新的治疗策略. 抑制MCAK使TNBC细胞对帕克利塔塞尔敏感,可能改善这种致命的癌症亚型的治疗结果.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 遗传学 是一个遗传学.
背景情况:
- 三阴性乳腺癌 (TNBC) 是一种具有有限治疗选择的侵袭性亚型.
- 像帕克利塔塞尔这样的当前疗法会诱导形体,但会导致耐药性和神经病变.
- MCAK (线粒体中粒体关联基因素) 调节微管的动态,并限制动态积分.
研究的目的:
- 研究MCAK作为TNBC治疗点.
- 为了确定MCAK的新型抑制剂.
- 评估MCAK作为预后生物标志物的作用.
主要方法:
- 对TNBC中MCAK表达的公开可用的数据集的分析.
- 在ChemBridge 50k库中使用FRET和基于图像的测试对MCAK抑制剂进行体外查.
- 在MCAK抑制或淘汰后进行细胞活力和药物敏感性测定.
主要成果:
- 在TNBC中,MCAK被上调,与更差的预后相关.
- 抑制或淘汰MCAK可以降低TNBC细胞中的帕克利塔塞尔IC50.
- 确定了三种新的MCAK抑制剂,其中C4使TNBC细胞对帕克利塔塞尔敏感,并降低了克隆原生存活率.
结论:
- MCAK是一种潜在的预后生物标志物和TNBC的治疗标.
- 新型MCAK抑制剂在临床前TNBC模型中显示出有效性.
- 针对MCAK提供了一种有前途的策略,以克服对标杆菌的耐药性并改善TNBC治疗.
相关概念视频
Inhibition of Cdk Activity
4.8K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.8K
Nondisjunction
3.9K
Nondisjunction is the failure of homologous chromosomes or sister chromatids to separate correctly and move to the opposite poles of the cells. This produces daughter cells with abnormal chromosome numbers. Nondisjunction is common during anaphase I or anaphase II of meiosis. Mutations in synaptonemal complex proteins that attach homologous chromosomes increase the chances of nondisjunction in anaphase I of meiosis I. In contrast, mutations in topoisomerases and condensins that hold...
3.9K


